● Multi-year strategic collaboration in target discovery and therapeutic development
based on Scenic Biotech’s disease modifying approach
● Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse of
genetic modifiers
● Scenic Biotech will receive an undisclosed upfront payment and is eligible to receive
milestone payments and royalties across multiple products meeting certain predefined
conditions


Amsterdam, The Netherlands, September 21, 2020 – Scenic Biotech BV (“Scenic”), a pioneer
in the discovery of genetic modifiers to enable the development of disease modifying
therapeutics for rare genetic disorders and other devastating illnesses, today announced
that it has entered into a multi-year strategic collaboration with Genentech, a member of
the Roche Group, to discover, develop and commercialize novel therapeutics that target
genetic modifiers.


Genetic modifiers are genes that counteract the effect of a disease-causing gene. They may
explain why some people with genetic mutations linked to severe disease end up having
only mild or no symptoms. Also known as disease suppressors, genetic modifiers therefore
positively influence the severity of disease and act as a ‘natural form of protection’. Their
discovery is leading to a completely new class of drug targets.


Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data
warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas. The
collaboration enables Genentech to select multiple targets for further development with an
option to extend the collaboration. Scenic will receive an undisclosed upfront payment and
is eligible to receive additional target selection fees for drug targets taken forward by
Genentech. In addition, Scenic is eligible for success-based payments for each target based
on achievement of certain predetermined milestones, as well as royalties on sales of certain
products resulting from the collaboration. Total deal value could exceed US $375M.


Scenic has built an extensive proprietary data warehouse of genetic modifiers and its Cell-
Seq platform enables the development of potential disease modifying therapeutics for
devastating diseases with an in-house focus on inherited rare diseases and immunooncology/
inflammation.


The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and
Oxford University and recently appointed Oscar Izeboud, PhD as its Chief Executive Officer.
Dr Sebastian Nijman, Co-founder and CSO of Scenic Biotech said:
“Genentech is the pioneer in innovative biotech and has world leading research and
development capabilities. Scenic is a science-driven company and having Genentech as our
first major industry partner is a great validation of our technology and by working together
it will extend the utility of our platform beyond our current therapeutic areas of interest. The
collaboration also brings significant strategic value for Scenic as it enables us to realise the
potential of our genetic modifier expertise alongside independently advancing our own
programs towards clinical development.”


Notes to Editors
About Scenic Biotech
Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease
targets, for drug intervention. Also known as disease suppressors, genetic modifiers are
genes that act to suppress or completely block the effect of a disease-causing mutated
gene.


As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of
genetic modifiers and has already identified a number of novel genetic modifiers for over a
dozen inherited diseases. This approach is enabling the development of disease modifying
therapeutics for devastating diseases including inherited rare diseases and cancer.
Scenic Biotech is headquartered in Amsterdam, the Netherlands. The Company was
founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University,
backed by a Dutch-UK syndicate of Venture Capital investors that include BioGeneration
Ventures, Inkef Capital, and Oxford Sciences Innovation.
Scenic Biotech refers to all companies within the Scenic group, comprising Scenic Holding BV
and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech
BV.


For further information please visit: www.scenicbiotech.com
For Further information, please contact:
At the Company
info@scenicbiotech.com
Media Enquiries – Scenic Biotech
Sue Charles, Charles Consultants, sue.charles59@outlook.com, +44 (0)7986 726585